Olvion (Sildenafil)

Sildenafil, the active ingredient in Olvion, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for oral use. It treats erectile dysfunction in adult males. GNH USA supplies Olvion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olvion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olvion is a PDE5 inhibitor used in the management of conditions affecting the male sexual response pathway.

- Erectile dysfunction: improves ability to achieve and maintain an erection suitable for sexual activity. - Pulmonary arterial hypertension: helps lower pulmonary arterial pressure and improve exercise capacity. - Secondary Raynaud's phenomenon: may reduce frequency of vasospastic attacks in affected individuals. - Benign prostatic hyperplasia (BPT) associated lower urinary tract symptoms: may provide modest improvement in urinary flow. - Male infertility related to erectile dysfunction: supports sexual performance that can aid natural conception. - Psychological erectile dysfunction: assists when performance anxiety contributes to the condition.

Olvion may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness, typically on the face or neck. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy or runny nose. - Visual disturbances: blurred vision or changes in colour perception. - Myalgia: muscle aches, often in the back or limbs.

Serious or Rare Side Effects: - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy). - Sudden hearing loss or ringing in the ears. - Priapism: prolonged erection lasting more than four hours. - Severe hypotension: marked drop in blood pressure, especially with nitrates. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

Before prescribing Olvion, clinicians should assess cardiovascular status and review concomitant medications.

- Cardiovascular disease: evaluate risk of myocardial ischemia during sexual activity. - Nitrate therapy: avoid co‑administration due to risk of severe hypotension. - Alpha‑blockers: use with caution, monitor blood pressure closely. - Liver or kidney impairment: consider dose adjustment and monitor function. - Visual or auditory disorders: assess baseline status and monitor for changes. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olvion can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Nitrates: concurrent use can cause profound hypotension. - Guanylate cyclase stimulators: may amplify vasodilatory effects. - Certain antifungal agents (e.g., ketoconazole): increase sildenafil plasma levels.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may cause additive blood pressure lowering. - Antihypertensives: monitor for enhanced hypotensive response. - Protease inhibitors (e.g., ritonavir): may raise sildenafil concentrations. - Macrolide antibiotics (e.g., erythromycin): potential increase in drug exposure.